FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study

Background: In preclinical gastric cancer (GC) models, FGFR2 amplification was associated with increased tumour cell proliferation and survival, and drugs targeting this pathway are now in clinical trials. Methods: FGFR2 FISH was performed on 961 GCs from the United Kingdom, China and Korea, and the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2014-02, Vol.110 (4), p.967-975
Hauptverfasser:	Su, X, Zhan, P, Gavine, P R, Morgan, S, Womack, C, Ni, X, Shen, D, Bang, Y-J, Im, S-A, Ho Kim, W, Jung, E-J, Grabsch, H I, Kilgour, E
Format:	Artikel
Sprache:	eng
Schlagworte:	631/208/737/1505 692/699/67/1504/1829 692/700/1750 Adolescent Adult Aged Aged, 80 and over Biological and medical sciences Biomarkers, Tumor - genetics Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Cell growth Chemotherapy China Cohort Studies Drug Resistance Epidemiology Female Gastric cancer Gastroenterology. Liver. Pancreas. Abdomen Gene Amplification Gene Expression Regulation, Neoplastic Hospitals Humans In Situ Hybridization, Fluorescence Kinases Lymphatic Metastasis Male Medical prognosis Medical research Medical sciences Medicine Middle Aged Molecular Diagnostics Molecular Medicine Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Oncology Pathology Patients Prognosis Receptor, ErbB-2 - genetics Receptor, Fibroblast Growth Factor, Type 2 - genetics Republic of Korea Stomach Neoplasms - genetics Stomach Neoplasms - mortality Stomach Neoplasms - pathology Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Survival Tumors United Kingdom Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background: In preclinical gastric cancer (GC) models, FGFR2 amplification was associated with increased tumour cell proliferation and survival, and drugs targeting this pathway are now in clinical trials. Methods: FGFR2 FISH was performed on 961 GCs from the United Kingdom, China and Korea, and the relationship with clinicopathological data and overlap with HER2 amplification were analysed. Results: The prevalence of FGFR2 amplification was similar between the three cohorts (UK 7.4%, China 4.6% and Korea 4.2%), and intratumoral heterogeneity was observed in 24% of FGFR2 amplified cases. FGFR2 amplification was associated with lymph node metastases ( P
ISSN:	0007-0920 1532-1827
DOI:	10.1038/bjc.2013.802